Infinity Pharmaceuticals Announces Conference Call for the ASCO Genitourinary Cancers Symposium to Discuss Clinical Data from...
February 10 2021 - 04:05PM
Business Wire
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage
biotechnology company developing eganelisib, a potentially
first-in-class, oral, immuno-oncology macrophage reprogramming
therapeutic, which addresses a fundamental biologic mechanism of
immune suppression in cancer, today announced that it will hold a
conference call on Thursday, February 11, 2021 at 7:30 a.m. ET to
discuss clinical data from MARIO-275 (Macrophage Reprogramming In Immuno-Oncology), a Phase 2 randomized,
placebo-controlled study of eganelisib combined with Opdivo®
(nivolumab) in I/O naïve urothelial cancer.
Conference Call Information
A live webcast of the conference call can be accessed in the
"Investors/Media" section of Infinity's website at www.infi.com. To
participate in the conference call, please dial (877) 316-5293
(domestic) and (631) 291-4526 (international) five minutes prior to
start time. The conference ID number is 2485636. An archived
version of the webcast will be available on Infinity's website for
30 days.
ASCO Genitourinary Cancers Symposium
Poster Presentation Details
Title:
Preliminary Analysis of a Phase
2, Multicenter, Randomized, active-Control Study to Evaluate the
Efficacy and Safety of Eganelisib (IPI-549) in Combination with
Nivolumab Compared to Nivolumab Monotherapy in Patients with
Advanced Urothelial Carcinoma
Presenter:
Piotr Tomczak, M.D., Ph.D.
Date:
February 11th at 8am ET
About Infinity and Eganelisib
Infinity is an innovative biopharmaceutical company dedicated to
developing novel medicines for people with cancer. Infinity is
advancing eganelisib, a potentially first-in-class, oral,
immuno-oncology macrophage reprogramming therapeutic which
addresses a fundamental biologic mechanism of immune suppression in
cancer, in multiple clinical studies. MARIO-275 is a Phase 2,
randomized, placebo-controlled study of eganelisib combined with
Opdivo in I/O naïve urothelial cancer. MARIO-3 is the first
eganelisib combination study in front-line advanced cancer patients
and is evaluating eganelisib in combination with Tecentriq® and
Abraxane® in front-line TNBC and in combination with Tecentriq and
Avastin® in front-line RCC. In collaboration with Arcus
Biosciences, Infinity is evaluating a checkpoint inhibitor-free,
novel combination regimen of eganelisib plus etrumadenant (dual
adenosine receptor antagonist) plus Doxil® in advanced TNBC
patients. With these studies Infinity is evaluating eganelisib in
the anti-PD-1 refractory, I/O-naïve, and front-line and second line
settings. For more information on Infinity, please refer to
Infinity's website at www.infi.com.
Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc. Abraxane®
is a registered trademark of Abraxis BioScience, LLC a wholly owned
subsidiary of Bristol Myers Squibb Company. Avastin® is a
registered trademark of Genentech, Inc. Doxil® is a registered
trademark of Baxter Healthcare Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210210005916/en/
Investor Relations Contact: Ashley Robinson LifeSci
Advisors, LLC 617-775-5956
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Mar 2023 to Mar 2024